BioMarin Pharmaceutical Ownership | Who Owns BioMarin Pharmaceutical?


OverviewForecastRevenueFinancialsChartTranscripts

BioMarin Pharmaceutical Ownership Summary


BioMarin Pharmaceutical is owned by 31.91% institutional investors, 0.30% insiders, and 67.79% retail investors. Blackrock is the largest institutional shareholder, holding 12.04% of BMRN shares. Dodge & Cox Stock I is the top mutual fund, with 5.08% of its assets in BioMarin Pharmaceutical shares.

BMRN Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockBioMarin Pharmaceutical31.91%0.30%67.79%
SectorHealthcare Stocks 35.42%11.83%52.76%
IndustryBiotech Stocks 35.46%11.78%52.76%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock22.74M12.04%$1.87B
Blackrock funding, inc. /de19.82M10.33%$1.12B
Vanguard group18.13M9.46%$1.08B
Dodge & cox14.56M7.59%$822.59M
Primecap management co/ca/14.19M7.40%$801.82M
Aqr capital management7.68M4.00%$429.35M
Norges bank7.53M3.93%$447.57M
State street7.30M3.80%$412.10M
Viking global investors lp7.06M3.68%$398.94M
Citadel advisors4.51M2.35%$254.92M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Krensavage asset management524.79K11.59%$29.64M
Boone capital management547.87K9.48%$30.95M
Palo alto investors lp685.18K5.92%$38.71M
Vestal point capital, lp3.58M5.65%$201.95M
Eagle health investments lp505.81K5.00%$28.57M
Sector gamma as239.92K3.20%$13.55M
Camber capital management lp600.00K3.10%$32.98M
Novo660.00K3.02%$37.28M
Arrowpoint investment partners (singapore) pte.48.72K2.45%$2.75M
Sofinnova investments781.98K1.68%$44.17M

Top Buyers

HolderShares% AssetsChange
Blackrock22.74M0.04%8.26M
Norges bank7.53M0.05%7.53M
Citadel advisors4.51M0.04%3.15M
Fmr3.57M0.01%1.73M
Balyasny asset management1.36M0.10%1.36M

Top Sellers

HolderShares% AssetsChange
Elliott investment management---3.50M
Squarepoint ops359.70K0.02%-1.47M
Avoro capital advisors---1.46M
Deep track capital, lp1.15M1.06%-1.15M
Morgan stanley1.32M0.00%-993.96K

New Positions

HolderShares% AssetsChangeValue
Norges bank7.53M0.05%7.53M$447.57M
Vanguard fiduciary trust1.19M0.02%1.19M$67.46M
Deerfield management company, l.p. (series c)851.56K0.57%851.56K$48.10M
Rubric capital management lp440.56K0.26%440.56K$24.89M
Axa investment managers362.95K0.05%362.95K$19.66M

Sold Out

HolderChange
Blume capital management-2.00
Advisornet financial-3.00
Householder group estate & retirement specialist-3.00
Raleigh capital management-4.00
Tortoise investment management-4.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 2026328-42.35%61,195,485-67.48%310.33%168-35.88%86-60.37%
Dec 31, 2025386-36.30%120,381,244-32.95%620.71%173-43.09%149-25.13%
Sep 30, 2025521-13.60%148,245,021-13.91%770.96%255-20.56%182-1.62%
Jun 30, 2025611-0.97%183,457,4080.41%951.05%322-5.57%1886.82%
Mar 31, 202511-98.11%305,544-99.83%-0.00%7-97.61%1-99.45%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Dodge & Cox Stock I9.77M5.08%-
Capital Group Growth Fnd of Amer Comp8.28M4.32%741.56K
American Funds Growth Fund of Amer A8.28M4.32%741.56K
iShares Core S&P Mid-Cap ETF6.49M3.36%-3.26K
Vanguard Total Stock Mkt Idx Inv6.14M3.18%15.56K
Vanguard US Total Market Shares ETF6.04M3.15%4.43K
Vanguard PRIMECAP Inv5.17M2.68%-123.80K
Vanguard Capital Opportunity Inv5.10M2.64%-118.50K
American Funds AMCAP A4.49M2.36%-115.70K
Capital Group AMCAP Composite4.49M2.36%-115.70K

Recent Insider Transactions


DateNameRoleActivityValue
May 07, 2026Friberg Gregory R EVP, Chief R&D OfficerSell$176.68K
Mar 11, 2026Guyer Charles Greg EVP, Chief Technical OfficerSell$996.74K
Feb 26, 2026Friberg Gregory R EVP, Chief R&D OfficerSell$381.94K
Feb 26, 2026Davis George Eric EVP, Chief Legal OfficerSell$1.60M
May 20, 2025Burkhart Erin GVP, Chief Accounting OfficerSell$105.93K

Insider Transactions Trends


DateBuySell
2026 Q2-1
2026 Q1-3
2025 Q4--
2025 Q3--
2025 Q2-2

BMRN Ownership FAQ


Who Owns BioMarin Pharmaceutical?

BioMarin Pharmaceutical shareholders are primarily institutional investors at 31.91%, followed by 0.30% insiders and 67.79% retail investors. The average institutional ownership in BioMarin Pharmaceutical's industry, Biotech Stocks , is 35.46%, which BioMarin Pharmaceutical falls below.

Who owns the most shares of BioMarin Pharmaceutical?

BioMarin Pharmaceutical’s largest shareholders are Blackrock (22.74M shares, 12.04%), Blackrock funding, inc. /de (19.82M shares, 10.33%), and Vanguard group (18.13M shares, 9.46%). Together, they hold 31.83% of BioMarin Pharmaceutical’s total shares outstanding.

Does Blackrock own BioMarin Pharmaceutical?

Yes, BlackRock owns 12.04% of BioMarin Pharmaceutical, totaling 22.74M shares as of Jun 2024. This represents 0.04% of BlackRock's total assets, with a market value of 1.87B$. In the last quarter, BlackRock increased its holdings by 8.26M shares, a 57.05% change.

Who is BioMarin Pharmaceutical’s biggest shareholder by percentage of total assets invested?

Krensavage asset management is BioMarin Pharmaceutical’s biggest shareholder by percentage of total assets invested, with 11.59% of its assets in 524.79K BioMarin Pharmaceutical shares, valued at 29.64M$.

Who is the top mutual fund holder of BioMarin Pharmaceutical shares?

Dodge & Cox Stock I is the top mutual fund holder of BioMarin Pharmaceutical shares, with 5.08% of its total shares outstanding invested in 9.77M BioMarin Pharmaceutical shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools